Genetic variants mimicking beta-blocker and calcium-channel blocker drug targets reduced preeclampsia risk by 7% per 1 mmHg blood pressure decrease in 671,922 pregnant women. The study used Mendelian randomization to examine ADRB1 and CACNB2 gene variants, which naturally lower blood pressure similar to pharmaceutical interventions. This genetic approach circumvents ethical limitations of testing antihypertensive drugs directly in pregnant populations, where randomized trials remain scarce due to safety concerns. The findings suggest these drug classes may offer protective benefits against pregnancy hypertension disorders, with potential additional reductions in miscarriage, preterm birth, and growth restriction, though these secondary effects showed greater uncertainty. The research addresses a critical clinical gap, as pregnancy hypertension affects millions globally and remains a leading cause of maternal mortality. However, this preprint awaits peer review, and results may change upon further scrutiny. The genetic evidence provides compelling but indirect support for targeted antihypertensive therapy during pregnancy, potentially informing future clinical guidelines when traditional trial evidence proves challenging to obtain.